<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2016-3-81-86</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-706</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Остеоартроз: современные принципы лечения и предпосылки д ля разработки персонифицированной терапии</article-title><trans-title-group xml:lang="en"><trans-title>Osteoarthritis: Current treatment principles and prerequisites for the development of personified therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Олюнин</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Olyunin</surname><given-names>Yu. A.</given-names></name></name-alternatives><email xlink:type="simple">yuryaolyunin@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия 115522, Москва, Каширское шоссе, 34А</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>26</day><month>09</month><year>2016</year></pub-date><volume>10</volume><issue>3</issue><fpage>81</fpage><lpage>86</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Олюнин Ю.А., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Олюнин Ю.А.</copyright-holder><copyright-holder xml:lang="en">Olyunin Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/706">https://mrj.ima-press.net/mrj/article/view/706</self-uri><abstract><p>Остеоартроз (ОА) является не единой нозологической формой, а группой заболеваний, имеющих различное происхождение. Тем не менее сходство морфологических и клинических проявлений этих болезней определяет общность подхода к их диагностике и лечению. Неоднозначные результаты, полученные в ряде исследований, посвященных лечению ОА, во многом могут быть связаны с неоднородностью включенных в них групп больных. Развитие ОА является следствием сочетанного действия многих факторов, не исключено, что у части больных некоторые из этих факторов могут приобретать доминирующее значение, определяя формирование особых вариантов ОА. Вероятно, могут быть выделены несколько таких вариантов: метаболический, воспалительный, травматический и вариант, связанный с изменениями субхондральной кости. Лечение, подобранное с учетом патогенетического варианта болезни, могло бы обеспечить более благоприятные результаты, чем терапия, которая проводится в соответствии со стандартными рекомендациями. Однако на сегодняшний день мы не имеем четких критериев, которые позволяли бы сформировать соответствующие группы пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Osteoarthritis (OA) is not a single nosological entity, but it is a group of diseases with different origins. Nevertheless, the similarity of morphological and clinical manifestations of these diseases determines a common approach to their diagnosis and treatment. The ambiguous results obtained in a number of studies dealing with the treatment of OA can be largely associated with the heterogeneity of included patient groups. The development of OA is the result of combined influence of many factors; it is not inconceivable that some of these factors in some patients may assume a dominant importance, determining the development of special OA types. It is likely that a few of these types: metabolic, inflammatory, traumatic, and subchondral bone change-induced ones, can be identified. The therapy chosen in terms of the pathogenetic type of the disease could provide better results than that performed in accordance with standard recommendations. However, today there are no clear criteria that could form appropriate patient groups.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартроз</kwd><kwd>лечение</kwd><kwd>рекомендации</kwd><kwd>метаболический синдром</kwd><kwd>воспаление</kwd><kwd>субхондральная кость</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthritis</kwd><kwd>treatment</kwd><kwd>recommendations</kwd><kwd>metabolic syndrome</kwd><kwd>inflammation</kwd><kwd>subchondral bone</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Цветкова ЕС, Иониченок НГ, Денисов ЛН. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь-модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно- практическая ревматология. 2015;53(1):63-8. [Tsvetkova ES, Ionichenok NG, Denisov LN. Current pharmacotherapy for knee osteoarthritis: specific features of symptomatic and disease modifying effects. Communication 1. specific features of the symptomatic effects of current drugs to treat knee ostheoarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(1):63-8. (In Russ.)]. doi: 10.14412/1995-4484- 2015-63-68.</mixed-citation><mixed-citation xml:lang="en">Цветкова ЕС, Иониченок НГ, Денисов ЛН. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь-модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно- практическая ревматология. 2015;53(1):63-8. [Tsvetkova ES, Ionichenok NG, Denisov LN. Current pharmacotherapy for knee osteoarthritis: specific features of symptomatic and disease modifying effects. Communication 1. specific features of the symptomatic effects of current drugs to treat knee ostheoarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(1):63-8. (In Russ.)]. doi: 10.14412/1995-4484- 2015-63-68.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Стребкова ЕА, Алексеева ЛИ. Остеоартроз и ожирение. Научно-практическая ревматология. 2015;53(5):542-52. [Strebkova EA, Alekseeva LI. Osteoarthritis and obesity. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(5):542-52. (In Russ.)]. doi: 10.14412/1995-4484-2015-542-552.</mixed-citation><mixed-citation xml:lang="en">Стребкова ЕА, Алексеева ЛИ. Остеоартроз и ожирение. Научно-практическая ревматология. 2015;53(5):542-52. [Strebkova EA, Alekseeva LI. Osteoarthritis and obesity. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(5):542-52. (In Russ.)]. doi: 10.14412/1995-4484-2015-542-552.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandes L, Hagen KB, Bijlsma JW, et al; European League Against Rheumatism (EULAR). EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis. 2013 Jul;72(7):1125-35. doi: 10.1136/ annrheumdis-2012- 202745.</mixed-citation><mixed-citation xml:lang="en">Fernandes L, Hagen KB, Bijlsma JW, et al; European League Against Rheumatism (EULAR). EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis. 2013 Jul;72(7):1125-35. doi: 10.1136/ annrheumdis-2012- 202745.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева ЛИ. Рекомендации по ведению больных остеоартрозом коленных суставов в реальной клинической практике. Лечащий врач. 2015;(1):64-9. [Alekseeva LI. Recommendations for the management of patients with osteoarthritis of the knee in clinical practice. Lechashchii vrach. 2015;(1):64-9. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Алексеева ЛИ. Рекомендации по ведению больных остеоартрозом коленных суставов в реальной клинической практике. Лечащий врач. 2015;(1):64-9. [Alekseeva LI. Recommendations for the management of patients with osteoarthritis of the knee in clinical practice. Lechashchii vrach. 2015;(1):64-9. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3): 363-88. doi: 10.1016/j.joca.2014.01.003.</mixed-citation><mixed-citation xml:lang="en">McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3): 363-88. doi: 10.1016/j.joca.2014.01.003.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bruyеre O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014.</mixed-citation><mixed-citation xml:lang="en">Bruyеre O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Craig DG, Bates CM, Davidson JS, et al. Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol. 2012 Feb;73(2):285-94. doi: 10.1111/j.1365- 2125.2011.04067.x.</mixed-citation><mixed-citation xml:lang="en">Craig DG, Bates CM, Davidson JS, et al. Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity. Br J Clin Pharmacol. 2012 Feb;73(2):285-94. doi: 10.1111/j.1365- 2125.2011.04067.x.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ассоциация ревматологов России. Проект Национальных рекомендаций по ревматологии. Лечение остеоартроза. [Association of rheumatologists of Russia. Draft of National guidelines for rheumatology. The treatment of osteoarthritis.]. http://www.rheumatolog.ru/system/files/pdf/nacrec/natrec14.pdf.</mixed-citation><mixed-citation xml:lang="en">Ассоциация ревматологов России. Проект Национальных рекомендаций по ревматологии. Лечение остеоартроза. [Association of rheumatologists of Russia. Draft of National guidelines for rheumatology. The treatment of osteoarthritis.]. http://www.rheumatolog.ru/system/files/pdf/nacrec/natrec14.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Алексеева ЛИ. Анальгетическое лечение с использованием системного алгоритма. Современная ревматология. 2015;9(2):37-50. [Karateev AE, Alekseeva LI. Analgesic treatment, by using a systemic algorithm. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(2):37-50. (In Russ.)]. doi: 10.14412/1996-7012-2015-2-37-50.</mixed-citation><mixed-citation xml:lang="en">Каратеев АЕ, Алексеева ЛИ. Анальгетическое лечение с использованием системного алгоритма. Современная ревматология. 2015;9(2):37-50. [Karateev AE, Alekseeva LI. Analgesic treatment, by using a systemic algorithm. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(2):37-50. (In Russ.)]. doi: 10.14412/1996-7012-2015-2-37-50.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Conforti A, Leone R, Moretti U, et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24(14):1081-90.</mixed-citation><mixed-citation xml:lang="en">Conforti A, Leone R, Moretti U, et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24(14):1081-90.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411-20.</mixed-citation><mixed-citation xml:lang="en">Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411-20.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Лучихина ЕЛ. Нимесулид при ревматоидном артрите. Современная ревматология. 2015;9(2):75-82. [Luchikhina EL. Nimesulide in rheumatoid arthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(2):75-82. (In Russ.)]. doi: 10.14412/1996-7012-2015-2-75-82.</mixed-citation><mixed-citation xml:lang="en">Лучихина ЕЛ. Нимесулид при ревматоидном артрите. Современная ревматология. 2015;9(2):75-82. [Luchikhina EL. Nimesulide in rheumatoid arthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(2):75-82. (In Russ.)]. doi: 10.14412/1996-7012-2015-2-75-82.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rainsford KD; Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006 Jun;22(6):1161-70.</mixed-citation><mixed-citation xml:lang="en">Rainsford KD; Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006 Jun;22(6):1161-70.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kriegel W, Korff KJ, Ehrlich JC, et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract. 2001 Oct;55(8):510-4.</mixed-citation><mixed-citation xml:lang="en">Kriegel W, Korff KJ, Ehrlich JC, et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract. 2001 Oct;55(8):510-4.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Олюнин ЮА. Локальная терапия нестероидными противовоспалительными препаратами при ревматических болезнях. Consilium medicum. 2012;14(9):106-10. [Olyunin YuA. Local therapy with nonsteroidal anti-inflammatory drugs in rheumatic diseases. Consilium medicum. 2012;14(9):106-10. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Олюнин ЮА. Локальная терапия нестероидными противовоспалительными препаратами при ревматических болезнях. Consilium medicum. 2012;14(9):106-10. [Olyunin YuA. Local therapy with nonsteroidal anti-inflammatory drugs in rheumatic diseases. Consilium medicum. 2012;14(9):106-10. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ergü n H, Kü lcü D, Kutlay S, et al. Efficacy and safety of topical nimesulide in the treatment of knee osteoarthritis. J Clin Rheumatol. 2007 Oct;13(5):251-5</mixed-citation><mixed-citation xml:lang="en">Ergü n H, Kü lcü D, Kutlay S, et al. Efficacy and safety of topical nimesulide in the treatment of knee osteoarthritis. J Clin Rheumatol. 2007 Oct;13(5):251-5</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hochberg MC, Altman RD, April KT, et al; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74.</mixed-citation><mixed-citation xml:lang="en">Hochberg MC, Altman RD, April KT, et al; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001 Jan 27;357(9252):251-6.</mixed-citation><mixed-citation xml:lang="en">Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001 Jan 27;357(9252):251-6.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011 Jun;70(6):982-9</mixed-citation><mixed-citation xml:lang="en">Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011 Jun;70(6):982-9</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ. Лечение остеоартроза с точки зрения безопасности фармакотерапии. Современная ревматология. 2009;3(1):51-7. [Karateev AE. Treating osteoarthrosis in terms of the safety of pharmacotherapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2009;3(1): 51-7. (In Russ.)]. doi: 10.14412/1996-7012- 2009-524.</mixed-citation><mixed-citation xml:lang="en">Каратеев АЕ. Лечение остеоартроза с точки зрения безопасности фармакотерапии. Современная ревматология. 2009;3(1):51-7. [Karateev AE. Treating osteoarthrosis in terms of the safety of pharmacotherapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2009;3(1): 51-7. (In Russ.)]. doi: 10.14412/1996-7012- 2009-524.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ. Достоинства и недостатки диацереина. Современная ревматология. 2014;8(4):90-5. [Karateev AE. Diacerein: Advantages and disadvantages. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;8(4):90-5. (In Russ.)]. doi: 10.14412/1996-7012-2014- 4-90-95.</mixed-citation><mixed-citation xml:lang="en">Каратеев АЕ. Достоинства и недостатки диацереина. Современная ревматология. 2014;8(4):90-5. [Karateev AE. Diacerein: Advantages and disadvantages. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;8(4):90-5. (In Russ.)]. doi: 10.14412/1996-7012-2014- 4-90-95.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Pelletier J, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10):2339-48. doi: 10.1002/15290131(200010)43:10&lt;2339::AIDANR23&gt;3.0.CO;2-P.</mixed-citation><mixed-citation xml:lang="en">Pelletier J, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10):2339-48. doi: 10.1002/15290131(200010)43:10&lt;2339::AIDANR23&gt;3.0.CO;2-P.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dougados M, Nguyen M, Berdah L, et al.; ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 2001 Nov;44(11):2539-47. doi: 10.1002/1529- 0131(200111)44:11&lt;2539::AIDART434&gt;3.0. CO;2-T.</mixed-citation><mixed-citation xml:lang="en">Dougados M, Nguyen M, Berdah L, et al.; ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 2001 Nov;44(11):2539-47. doi: 10.1002/1529- 0131(200111)44:11&lt;2539::AIDART434&gt;3.0. CO;2-T.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Karsdal MA, Christiansen C, Ladel C, et al. Osteoarthritis – a case for personalized health care? Osteoarthritis Cartilage. 2014 Jan;22(1):7-16. doi: 10.1016/j.joca.2013. 10.018.</mixed-citation><mixed-citation xml:lang="en">Karsdal MA, Christiansen C, Ladel C, et al. Osteoarthritis – a case for personalized health care? Osteoarthritis Cartilage. 2014 Jan;22(1):7-16. doi: 10.1016/j.joca.2013. 10.018.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone Spine. 2013 Dec;80(6):568-73. doi: 10.1016/j.jbspin.2013. 09.007.</mixed-citation><mixed-citation xml:lang="en">Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone Spine. 2013 Dec;80(6):568-73. doi: 10.1016/j.jbspin.2013. 09.007.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf E. Metabolic factors in osteoarthritis: obese people do not walk on their hands. Arthritis Res Ther. 2012 Jul 19;14(4):123. doi:10.1186/ar3894</mixed-citation><mixed-citation xml:lang="en">Yusuf E. Metabolic factors in osteoarthritis: obese people do not walk on their hands. Arthritis Res Ther. 2012 Jul 19;14(4):123. doi:10.1186/ar3894</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf E, Ioan-Facsinay A, Bijsterbosch J, et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis. 2011 Jul;70(7):1282-4. doi: 10.1136/ard.2010. 146282.</mixed-citation><mixed-citation xml:lang="en">Yusuf E, Ioan-Facsinay A, Bijsterbosch J, et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis. 2011 Jul;70(7):1282-4. doi: 10.1136/ard.2010. 146282.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis Cartilage. 2012 Nov;20(11):1217-26. doi: 10.1016/j.joca.2012. 06.006.</mixed-citation><mixed-citation xml:lang="en">Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis Cartilage. 2012 Nov;20(11):1217-26. doi: 10.1016/j.joca.2012. 06.006.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Rosa SC, Goncalves J, Judas F, et al. Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage. Arthritis Res Ther. 2009;11(3):R80. doi: 10.1186/ar2713.</mixed-citation><mixed-citation xml:lang="en">Rosa SC, Goncalves J, Judas F, et al. Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage. Arthritis Res Ther. 2009;11(3):R80. doi: 10.1186/ar2713.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Verzijl N, DeGroot J, Ben ZC, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum. 2002 Jan;46(1):114-23.</mixed-citation><mixed-citation xml:lang="en">Verzijl N, DeGroot J, Ben ZC, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum. 2002 Jan;46(1):114-23.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Стребкова ЕА, Соловьева ИВ, Шарапова ЕП и др. Оценка влияния медикаментозной терапии ожирения на клинические проявления остеоартроза коленных суставов у женщин с избыточной массой тела. Научно-практическая ревматология. 2015;53(4):391-6. [Strebkova EA, Solov'eva IV, Sharapova EP, et al. Evaluation of the impact of drug therapy for obesity on the clinical manifestations of knee osteoarthritis in overweight women. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(4):391-6. (In Russ.)]. doi: 10.14412/1995-4484- 2015- 391-396.</mixed-citation><mixed-citation xml:lang="en">Стребкова ЕА, Соловьева ИВ, Шарапова ЕП и др. Оценка влияния медикаментозной терапии ожирения на клинические проявления остеоартроза коленных суставов у женщин с избыточной массой тела. Научно-практическая ревматология. 2015;53(4):391-6. [Strebkova EA, Solov'eva IV, Sharapova EP, et al. Evaluation of the impact of drug therapy for obesity on the clinical manifestations of knee osteoarthritis in overweight women. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(4):391-6. (In Russ.)]. doi: 10.14412/1995-4484- 2015- 391-396.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Marshall M, Nicholls E, Kwok WY, et al. Erosive osteoarthritis: a more severe form of radiographic hand osteoarthritis rather than a distinct entity? Ann Rheum Dis. 2015 Jan;74(1):136-41. doi: 10.1136/annrheumdis- 2013-203948.</mixed-citation><mixed-citation xml:lang="en">Marshall M, Nicholls E, Kwok WY, et al. Erosive osteoarthritis: a more severe form of radiographic hand osteoarthritis rather than a distinct entity? Ann Rheum Dis. 2015 Jan;74(1):136-41. doi: 10.1136/annrheumdis- 2013-203948.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Балабанова РМ. Новый подход к лечению остеоартроза как хронического воспалительного заболевания. Современная ревматология. 2013;7(2):95-8. [Balabanova RM. A novel approach to treating osteoarthrosis as a chronic inflammatory disease. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(2): 95-8. (In Russ.)]. doi: 10.14412/1996-7012- 2013-2390.</mixed-citation><mixed-citation xml:lang="en">Балабанова РМ. Новый подход к лечению остеоартроза как хронического воспалительного заболевания. Современная ревматология. 2013;7(2):95-8. [Balabanova RM. A novel approach to treating osteoarthrosis as a chronic inflammatory disease. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(2): 95-8. (In Russ.)]. doi: 10.14412/1996-7012- 2013-2390.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Jin X, Beguerie JR, Zhang W, et al. Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Apr;74(4):703-10. doi: 10.1136/annrheumdis-2013-204494.</mixed-citation><mixed-citation xml:lang="en">Jin X, Beguerie JR, Zhang W, et al. Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Apr;74(4):703-10. doi: 10.1136/annrheumdis-2013-204494.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kingsbury SR, Tharmanathan P, Arden NK, et al. Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. Trials. 2015 Mar 4;16:77. doi: 10.1186/s13063-015-0602-8.</mixed-citation><mixed-citation xml:lang="en">Kingsbury SR, Tharmanathan P, Arden NK, et al. Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. Trials. 2015 Mar 4;16:77. doi: 10.1186/s13063-015-0602-8.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Chevalier X, Ravaud P, Maheu E, et al; French section of osteoarthritis. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis. 2015 Sep; 74(9):1697- 705. doi: 10.1136/annrheumdis- 2014-205348.</mixed-citation><mixed-citation xml:lang="en">Chevalier X, Ravaud P, Maheu E, et al; French section of osteoarthritis. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis. 2015 Sep; 74(9):1697- 705. doi: 10.1136/annrheumdis- 2014-205348.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева ЛИ, Зайцева ЕМ. Перспективные направления терапии остеоартроза. Научно-практическая ревматология. 2014;52(3):247-50. [Alekseeva LI, Zaitseva EM. Perspective directions of osteoarthritis therapy. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014; 52(3):247-50. (In Russ.)]. doi: 10.14412/1995- 4484-2014-247-250.</mixed-citation><mixed-citation xml:lang="en">Алексеева ЛИ, Зайцева ЕМ. Перспективные направления терапии остеоартроза. Научно-практическая ревматология. 2014;52(3):247-50. [Alekseeva LI, Zaitseva EM. Perspective directions of osteoarthritis therapy. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014; 52(3):247-50. (In Russ.)]. doi: 10.14412/1995- 4484-2014-247-250.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Finnilä MA, Thevenot J, Aho OM, et al. Association between subchondral bone structure and osteoarthritis histopathological grade. J Orthop Res. 2016 May 26. doi: 10.1002/jor.23312. [Epub ahead of print]</mixed-citation><mixed-citation xml:lang="en">Finnilä MA, Thevenot J, Aho OM, et al. Association between subchondral bone structure and osteoarthritis histopathological grade. J Orthop Res. 2016 May 26. doi: 10.1002/jor.23312. [Epub ahead of print]</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Barr AJ, Campbell TM, Hopkinson D, et al. A systematic review of the relationship between subchondral bone features, pain and structural pathology in peripheral joint osteoarthritis. Arthritis Res Ther. 2015 Aug 25;17:228. doi: 10.1186/s13075-015-0735-x.</mixed-citation><mixed-citation xml:lang="en">Barr AJ, Campbell TM, Hopkinson D, et al. A systematic review of the relationship between subchondral bone features, pain and structural pathology in peripheral joint osteoarthritis. Arthritis Res Ther. 2015 Aug 25;17:228. doi: 10.1186/s13075-015-0735-x.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Зайцева ЕМ. Причины боли при остеоартрозе и факторы прогрессирования заболевания. Научно-практическая ревматология. 2011;49(1):50-7. [Zaitseva EM. The causes of pain in osteoarthrosis and the factors of disease progression (a review of literature). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(1):50-7. (In Russ.)].doi: 10.14412/1995-4484-2011-867.</mixed-citation><mixed-citation xml:lang="en">Зайцева ЕМ. Причины боли при остеоартрозе и факторы прогрессирования заболевания. Научно-практическая ревматология. 2011;49(1):50-7. [Zaitseva EM. The causes of pain in osteoarthrosis and the factors of disease progression (a review of literature). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;49(1):50-7. (In Russ.)].doi: 10.14412/1995-4484-2011-867.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo- controlled trial. Ann Rheum Dis. 2013 Feb;72(2):179-86. doi: 10.1136/ annrheumdis-2012- 202231.</mixed-citation><mixed-citation xml:lang="en">Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo- controlled trial. Ann Rheum Dis. 2013 Feb;72(2):179-86. doi: 10.1136/ annrheumdis-2012- 202231.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Samuels J, Krasnokutsky S, Abramson SB. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis. 2008;66(3): 244-50.</mixed-citation><mixed-citation xml:lang="en">Samuels J, Krasnokutsky S, Abramson SB. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis. 2008;66(3): 244-50.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Phitak T, Pothacharoen P, Kongtawelert P. Comparison of glucose derivatives effects on cartilage degradation. BMC Musculoskelet Disord. 2010 Jul 15;11:162. doi: 10.1186/1471-2474-11-162.</mixed-citation><mixed-citation xml:lang="en">Phitak T, Pothacharoen P, Kongtawelert P. Comparison of glucose derivatives effects on cartilage degradation. BMC Musculoskelet Disord. 2010 Jul 15;11:162. doi: 10.1186/1471-2474-11-162.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Tamura T, Kosaka N, Ishiwa J, et al. Rhein, an active metabolite of diacerein, down- regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and upregulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis Cartilage. 2001 Apr;9(3):257-63.</mixed-citation><mixed-citation xml:lang="en">Tamura T, Kosaka N, Ishiwa J, et al. Rhein, an active metabolite of diacerein, down- regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and upregulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis Cartilage. 2001 Apr;9(3):257-63.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
